Medicenna Therapeutics Corp reports results for the quarter ended in December - Earnings Summary

Medicenna Therapeutics

09/02/2022 14:36

* Medicenna Therapeutics Corp  MDNA.TO  reported a quarterly
adjusted loss of 9 cents​​ per share for the quarter ended in
December. The mean expectation of five analysts for the quarter
was for a loss of 13 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * Medicenna Therapeutics Corp's reported EPS for the quarter
was a
loss of 9 cents​.
    * The mean earnings estimate of analysts had fallen by
about 6.3%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Medicenna Therapeutics Corp shares had risen by 12.9% this
quarter.
    * The company reported a quarterly loss of C$4.81 million.
    * Wall Street's median 12-month price target for Medicenna
Therapeutics Corp is C$9.90 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated February 9 at 02:36 p.m.
 ​All figures in Canadian dollars unless otherwise stated